33%), leukopenia (10% vs.
5%), diarrhea (10% vs.
<1%), anemia (8% vs.
5%), and febrile neutropenia (6% vs.
2%).
In the chemotherapy arm, 54% of patients received eribulin, 20% received vinorelbine, 13% received capecitabine, and 12% received gemcitabine.
The median PFS was 5.6 months (95% CI, 4.3–6.3; 166 events) in the sacituzumab govitecan arm and 1.7 months (95% CI, 1.5–2.6; 150 events) in the chemotherapy arm (HRdisease progression or death, 0.41; 95% CI, 0.32–0.52;P< .001).[62][Level of evidence A1] The median OS was 12.1 months (95% CI, 10.7–14.0) in the sacituzumab govitecan arm and 6.7 months (95% CI, 5.8–7.7) in the chemotherapy arm (HRdeath, 0.48; 95% CI, 0.38–0.59;P< .001).